Johnson & Johnson raised 2026 guidance. Johnson & Johnson stock gains 1.04 percent.

Published on 10/26/2026 at 11:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson raised its 2026 outlook on October 13, 2026. Johnson & Johnson stock costs EUR 237.50, 1.04 percent above Xetra.

Guidance and segment growth

On October 13, 2026, Johnson & Johnson lifted its full-year sales midpoint to USD 101.2 billion.
MedTech sales grew 2.5 percent in the third quarter of 2026.
Johnson & Johnson stock trades at EUR 237.50 at 11:33 a.m. CET at Lang & Schwarz on October 26, 2026, 1.04 percent above the Xetra close of October 23, 2026.

Pop art comic book illustration of a large beige adhesive bandage roll centered on a halftone dot background in cyan and magenta, bold black comic outlines, yellow starburst and red lightning bolt elements radiating outward, flat primary colors of red blu — Johnson Consumer Health im Pop Art Stil, US4781601046 Pflasterrolle mit Halftone und Comic Outlines, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) stock is trading at EUR 237.50 at Lang & Schwarz on October 26, 2026 at 11:33 a.m. CET, up 1.04 percent versus the Xetra close of October 23, 2026 at EUR 235.05. The company had raised its 2026 outlook after third-quarter sales reached USD 25.40 billion. For investors, the contrast between pharmaceutical growth and softer medical technology performance is central.

Guidance moved higher in October

In its October 13, 2026 release, Johnson & Johnson reported third-quarter revenue of USD 25.399 billion, up 5.9 percent from USD 23.993 billion in the third quarter of 2025. Adjusted earnings per share were USD 2.59, compared with USD 2.80 a year earlier.

The same release lifted full-year 2026 reported sales guidance to USD 101.0 billion to USD 101.4 billion, with a USD 101.2 billion midpoint versus USD 101.1 billion previously. Adjusted earnings-per-share guidance rose to USD 11.05 to USD 11.15, with a USD 11.10 midpoint versus USD 11.04.

What drives the guidance?

The answer is the segment split. Innovative Medicine sales reached USD 16.757 billion in the third quarter of 2026, while MedTech sales were USD 8.642 billion. In the company release, operational growth was 7.9 percent for Innovative Medicine and 2.5 percent for MedTech.

CNBC reported on October 13, 2026 that MedTech sales missed estimates of USD 8.71 billion. The company said the division remained below its internal performance standard, while the pharmaceutical business supplied the stronger growth contribution.

Three dates show the shift

On July 29, 2026, Johnson & Johnson set a reported-sales midpoint of USD 101.1 billion. On October 13, 2026, third-quarter revenue reached USD 25.399 billion and adjusted earnings per share were USD 2.59. On October 13, 2026, management raised the reported-sales midpoint to USD 101.2 billion.

Upcoming shareholder dates

The next substantiated dates are November 24, 2026, for the ex-dividend date and December 8, 2026, for the USD 1.34 quarterly dividend payment, according to MarketBeat. Johnson & Johnson also scheduled its Enterprise Business Review for December 8, 2026, according to the company's prepared remarks.

Stock trades above Xetra close

The euro quote places the stock EUR 2.45 above the prior Xetra reference. The Nasdaq-listed shares were last at USD 237.50 in the finance quote on October 26, 2026 at 10:58 a.m. ET, while the operational picture remains divided between the two major businesses.

Johnson & Johnson was trading at EUR 237.50 at Lang & Schwarz on October 26, 2026 at 11:33 a.m. CET, 1.04 percent above the Xetra close of October 23, 2026 at EUR 235.05. The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.